arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Stoke Therapeutics, Inc.

STOK
$29.22 ▲ +1.17 (+4.17%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Stoke Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield
Revenue Growth -32.5%
Op. Margin None
ROIC -18.9%
FCF / Share $-0.89
Trailing P/E
Price / Book 5.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.32M
↓ -32.5%
Net Income Profit after all expenses
$-50.00M
— 0.0%
Operating Margin Operating profit as % of sales
-405.3%
↓ -105.1% 14th
FCF / Share Free cash flow per share
$-0.89
↓ -102.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
42
Returns
42
Financial Health
3
Cash Quality
2

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters